
OptimizeRx To Report Q1 2023 Earnings
Company results from the first quarter of 2023 will be reported on the call on May 10.
Read more about Karina's views on eliminating barriers and physician frustration.
The new report updates our progress on our ESg efforts since the inaugural report published last year.
OptimizeRx was recognized as one of the 500 fastest-growing companies in The Americas for the fourth consecutive year
The Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $15 million of its outstanding common stock.
The patient services provider will license the electronic Hub technology which was introduced to the OptimizeRx suite of solutions through the EvinceMed acquisition in 2022.